Gray/White Matter Contrast in Parkinson’s Disease
Gray/white matter contrast (GWC) decreases with aging and has been found to be a useful MRI biomarker in Alzheimer’s disease (AD), but its utility in Parkinson’s disease (PD) patients has not been investigated. The aims of the study were to test whether GWC is sensitive to aging changes in PD patien...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-03-01
|
Series: | Frontiers in Aging Neuroscience |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fnagi.2018.00089/full |
id |
doaj-86f5a3d6e2df4b508f583ffa34d8ca16 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Carme Uribe Barbara Segura Hugo C. Baggio Alexandra Abos Anna I. Garcia-Diaz Anna Campabadal Anna Campabadal Maria J. Marti Maria J. Marti Maria J. Marti Francesc Valldeoriola Francesc Valldeoriola Francesc Valldeoriola Yaroslau Compta Yaroslau Compta Yaroslau Compta Nuria Bargallo Carme Junque Carme Junque Carme Junque |
spellingShingle |
Carme Uribe Barbara Segura Hugo C. Baggio Alexandra Abos Anna I. Garcia-Diaz Anna Campabadal Anna Campabadal Maria J. Marti Maria J. Marti Maria J. Marti Francesc Valldeoriola Francesc Valldeoriola Francesc Valldeoriola Yaroslau Compta Yaroslau Compta Yaroslau Compta Nuria Bargallo Carme Junque Carme Junque Carme Junque Gray/White Matter Contrast in Parkinson’s Disease Frontiers in Aging Neuroscience Parkinson’s disease gray/white matter contrast cortical thickness aging magnetic resonance imaging |
author_facet |
Carme Uribe Barbara Segura Hugo C. Baggio Alexandra Abos Anna I. Garcia-Diaz Anna Campabadal Anna Campabadal Maria J. Marti Maria J. Marti Maria J. Marti Francesc Valldeoriola Francesc Valldeoriola Francesc Valldeoriola Yaroslau Compta Yaroslau Compta Yaroslau Compta Nuria Bargallo Carme Junque Carme Junque Carme Junque |
author_sort |
Carme Uribe |
title |
Gray/White Matter Contrast in Parkinson’s Disease |
title_short |
Gray/White Matter Contrast in Parkinson’s Disease |
title_full |
Gray/White Matter Contrast in Parkinson’s Disease |
title_fullStr |
Gray/White Matter Contrast in Parkinson’s Disease |
title_full_unstemmed |
Gray/White Matter Contrast in Parkinson’s Disease |
title_sort |
gray/white matter contrast in parkinson’s disease |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Aging Neuroscience |
issn |
1663-4365 |
publishDate |
2018-03-01 |
description |
Gray/white matter contrast (GWC) decreases with aging and has been found to be a useful MRI biomarker in Alzheimer’s disease (AD), but its utility in Parkinson’s disease (PD) patients has not been investigated. The aims of the study were to test whether GWC is sensitive to aging changes in PD patients, if PD patients differ from healthy controls (HCs) in GWC, and whether the use of GWC data would improve the sensitivity of cortical thickness analyses to differentiate PD patients from controls. Using T1-weighted structural images, we obtained individual cortical thickness and GWC values from a sample of 90 PD patients and 27 controls. Images were processed with the automated FreeSurfer stream. GWC was computed by dividing the white matter (WM) by the gray matter (GM) values and projecting the ratios onto a common surface. The sample characteristics were: 52 patients and 14 controls were males; mean age of 64.4 ± 10.6 years in PD and 64.7 ± 8.6 years in controls; 8.0 ± 5.6 years of disease evolution; 15.6 ± 9.8 UPDRS; and a range of 1.5–3 in Hoehn and Yahr (H&Y) stage. In both PD and controls we observed significant correlations between GWC and age involving almost the entire cortex. When applying a stringent cluster-forming threshold of p < 0.0001, the correlation between GWC and age also involved the entire cortex in the PD group; in the control group, the correlation was found in the parahippocampal gyrus and widespread frontal and parietal areas. The GWC of PD patients did not differ from controls’, whereas cortical thickness analyses showed thinning in temporal and parietal cortices in the PD group. Cortical thinning remained unchanged after adjusting for GWC. GWC is a very sensitive measure for detecting aging effects, but did not provide additional information over other parameters of atrophy in PD. |
topic |
Parkinson’s disease gray/white matter contrast cortical thickness aging magnetic resonance imaging |
url |
http://journal.frontiersin.org/article/10.3389/fnagi.2018.00089/full |
work_keys_str_mv |
AT carmeuribe graywhitemattercontrastinparkinsonsdisease AT barbarasegura graywhitemattercontrastinparkinsonsdisease AT hugocbaggio graywhitemattercontrastinparkinsonsdisease AT alexandraabos graywhitemattercontrastinparkinsonsdisease AT annaigarciadiaz graywhitemattercontrastinparkinsonsdisease AT annacampabadal graywhitemattercontrastinparkinsonsdisease AT annacampabadal graywhitemattercontrastinparkinsonsdisease AT mariajmarti graywhitemattercontrastinparkinsonsdisease AT mariajmarti graywhitemattercontrastinparkinsonsdisease AT mariajmarti graywhitemattercontrastinparkinsonsdisease AT francescvalldeoriola graywhitemattercontrastinparkinsonsdisease AT francescvalldeoriola graywhitemattercontrastinparkinsonsdisease AT francescvalldeoriola graywhitemattercontrastinparkinsonsdisease AT yaroslaucompta graywhitemattercontrastinparkinsonsdisease AT yaroslaucompta graywhitemattercontrastinparkinsonsdisease AT yaroslaucompta graywhitemattercontrastinparkinsonsdisease AT nuriabargallo graywhitemattercontrastinparkinsonsdisease AT carmejunque graywhitemattercontrastinparkinsonsdisease AT carmejunque graywhitemattercontrastinparkinsonsdisease AT carmejunque graywhitemattercontrastinparkinsonsdisease |
_version_ |
1725194783726501888 |
spelling |
doaj-86f5a3d6e2df4b508f583ffa34d8ca162020-11-25T01:05:23ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652018-03-011010.3389/fnagi.2018.00089353755Gray/White Matter Contrast in Parkinson’s DiseaseCarme Uribe0Barbara Segura1Hugo C. Baggio2Alexandra Abos3Anna I. Garcia-Diaz4Anna Campabadal5Anna Campabadal6Maria J. Marti7Maria J. Marti8Maria J. Marti9Francesc Valldeoriola10Francesc Valldeoriola11Francesc Valldeoriola12Yaroslau Compta13Yaroslau Compta14Yaroslau Compta15Nuria Bargallo16Carme Junque17Carme Junque18Carme Junque19Medical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, SpainMedical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, SpainMedical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, SpainMedical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, SpainMedical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, SpainMedical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, SpainInstitute of Biomedical Research August Pi i Sunyer (IDIBAPS), Hospital Clinic, Barcelona, SpainInstitute of Biomedical Research August Pi i Sunyer (IDIBAPS), Hospital Clinic, Barcelona, SpainCentro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic de Barcelona, Barcelona, SpainParkinson’s Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institute of Neuroscience, University of Barcelona, Barcelona, SpainInstitute of Biomedical Research August Pi i Sunyer (IDIBAPS), Hospital Clinic, Barcelona, SpainCentro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic de Barcelona, Barcelona, SpainParkinson’s Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institute of Neuroscience, University of Barcelona, Barcelona, SpainInstitute of Biomedical Research August Pi i Sunyer (IDIBAPS), Hospital Clinic, Barcelona, SpainCentro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic de Barcelona, Barcelona, SpainParkinson’s Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institute of Neuroscience, University of Barcelona, Barcelona, SpainCentre de Diagnòstic per la Imatge, Hospital Clínic, Barcelona, SpainMedical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, SpainInstitute of Biomedical Research August Pi i Sunyer (IDIBAPS), Hospital Clinic, Barcelona, SpainCentro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic de Barcelona, Barcelona, SpainGray/white matter contrast (GWC) decreases with aging and has been found to be a useful MRI biomarker in Alzheimer’s disease (AD), but its utility in Parkinson’s disease (PD) patients has not been investigated. The aims of the study were to test whether GWC is sensitive to aging changes in PD patients, if PD patients differ from healthy controls (HCs) in GWC, and whether the use of GWC data would improve the sensitivity of cortical thickness analyses to differentiate PD patients from controls. Using T1-weighted structural images, we obtained individual cortical thickness and GWC values from a sample of 90 PD patients and 27 controls. Images were processed with the automated FreeSurfer stream. GWC was computed by dividing the white matter (WM) by the gray matter (GM) values and projecting the ratios onto a common surface. The sample characteristics were: 52 patients and 14 controls were males; mean age of 64.4 ± 10.6 years in PD and 64.7 ± 8.6 years in controls; 8.0 ± 5.6 years of disease evolution; 15.6 ± 9.8 UPDRS; and a range of 1.5–3 in Hoehn and Yahr (H&Y) stage. In both PD and controls we observed significant correlations between GWC and age involving almost the entire cortex. When applying a stringent cluster-forming threshold of p < 0.0001, the correlation between GWC and age also involved the entire cortex in the PD group; in the control group, the correlation was found in the parahippocampal gyrus and widespread frontal and parietal areas. The GWC of PD patients did not differ from controls’, whereas cortical thickness analyses showed thinning in temporal and parietal cortices in the PD group. Cortical thinning remained unchanged after adjusting for GWC. GWC is a very sensitive measure for detecting aging effects, but did not provide additional information over other parameters of atrophy in PD.http://journal.frontiersin.org/article/10.3389/fnagi.2018.00089/fullParkinson’s diseasegray/white matter contrastcortical thicknessagingmagnetic resonance imaging |